NYSE:PRGO - Perrigo Stock Price, Price Target & More

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Perrigo declared a quarterly dividend on Thursday, May 3rd. Investors of record on Friday, June 1st will be paid a dividend of $0.19 per share on Tuesday, June 19th. This represents a $0.76 annualized dividend and a yield of 1.00%. The ex-dividend date is Thursday, May 31st. View Perrigo's Dividend History.

Perrigo Company PLC (NYSE:PRGO) issued its quarterly earnings results on Tuesday, May, 8th. The company reported $1.26 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.12. The firm earned $1.22 billion during the quarter, compared to analysts' expectations of $1.21 billion. Perrigo had a net margin of 2.59% and a return on equity of 11.93%. The company's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.05 EPS. View Perrigo's Earnings History.

Perrigo is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Perrigo.

Perrigo updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $5.05-5.45 for the period, compared to the Thomson Reuters consensus estimate of $5.26.

17 equities research analysts have issued twelve-month target prices for Perrigo's stock. Their predictions range from $74.00 to $117.00. On average, they anticipate Perrigo's stock price to reach $93.3750 in the next twelve months. This suggests a possible upside of 23.0% from the stock's current price. View Analyst Ratings for Perrigo.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Perrigo include Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY) and Jazz Pharmaceuticals (JAZZ).

Media coverage about PRGO stock has trended positive this week, Accern reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Perrigo earned a media sentiment score of 0.28 on Accern's scale. They also assigned press coverage about the company an impact score of 45.74 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Perrigo's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (1.07%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.22%), Fisher Asset Management LLC (0.07%), Moon Capital Management LLC (0.03%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Perrigo stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, Jeffrey C Smith, Jeffrey Needham, John Wesolowski, Judy L Brown, Sharon Kochan, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.

PRGO stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Manning & Napier Group LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund, Gateway Investment Advisers LLC and Gofen & Glossberg LLC IL. Company insiders that have sold Perrigo company stock in the last year include Jeffrey Needham, John Wesolowski, Sharon Kochan, Thomas Farrington and Todd W Kingma. View Insider Buying and Selling for Perrigo.

PRGO stock was purchased by a variety of institutional investors in the last quarter, including Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, State of Alaska Department of Revenue, Moon Capital Management LLC, Xact Kapitalforvaltning AB and Stonebridge Capital Management Inc.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.

Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRGO stock can currently be purchased for approximately $75.90.

Perrigo has a market capitalization of $10.51 billion and generates $4.95 billion in revenue each year. The company earns $119.60 million in net income (profit) each year or $4.93 on an earnings per share basis. Perrigo employs 10,400 workers across the globe.

Perrigo's mailing address is TREASURY BUILDING LOWER GRAND CANAL STREET, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]